COMPARATIVE OF FIRST LINE MEDICATIONS FOR PRIMARY OPEN ANGLE GLAUCOMA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/zn936t28Keywords:
Glaucoma, medications, first line, POAGAbstract
Background: Glaucoma is the second leading cause of blindness globally, of which primary open-angle glaucoma (POAG) is the most common type, and its prevalence is estimated at 2% worldwide. The prevalence of glaucoma contributes to significant medical costs, and the majority of costs are medication related. Most medications used in the management of glaucoma are targeted at decreasing intraocular pressure (IOP), with each millimeter of mercury (mm Hg) IOP reduction shown to reduce the risk of glaucoma progression and subsequent vision loss by 10%.
The aim: This study aims to show the comparative of first line medications for primary open angle glaucoma.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search on SagePub brought up 124 articles. The results of the search conducted for the last year of 2013 yielded a total 12 articles for PubMed and 34 articles for SagePub. The result from title screening, a total 10 articles for PubMed and 12 articles for SagePub. In the end, we compiled a total of 8 papers. We included five research that met the criteria.
Conclusion: All active first-line drugs are among the most efficacious drugs, although the within class differences were small and may not be clinically meaningful. All factors, including adverse effects, patient preferences, and cost should be considered in selecting a drug for a given patient.
References
Garg A, Gazzard G. Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. Eye. 2020;34(1):60–71.
Cheema A, Chang RT, Shrivastava A, Singh K. Update on the medical treatment of primary open-angle glaucoma. Asia-Pacific J Ophthalmol. 2016;5(1):51–8.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma. Ophthalmology. 2016;123(1):129–40.
Shultz M, Chorbajian A, Zohouralen A. Comparative Effectiveness and Safety of Two Different Trabecular MIGS Devices With and Without Ab Interno Canaloplasty in Patients with Primary Open-Angle Glaucoma.
Ophthalmol Ther [Internet]. 2023;12(6):3307–22. Available from: https://doi.org/10.1007/s40123-023-00819-5
Balasopoulou A, Κokkinos P, Pagoulatos D, Plotas P, Makri OE, Georgakopoulos CD, et al. Symposium Recent advances and challenges in the management of retinoblastoma Globe ‑ saving Treatments. BMC Ophthalmol [Internet]. 2017;17(1):1. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28331284%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?arti d=PMC5354527%5Cnhttp://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-11-
%5Cnhttp://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886
Philippin H, Matayan E, Knoll KM, Macha E, Mbishi S, Makupa A, et al. Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Glob Heal. 2021;9(11):e1589–99.
Shi Y, Zhang Y, Sun W, Huang AS, Chen S, Zhang L, et al. 24-Hour efficacy of single primary selective laser trabeculoplasty versus latanoprost eye drops for Naïve primary open-angle glaucoma and ocular hypertension patients. Sci Rep [Internet]. 2023;13(1):1–10. Available from: https://doi.org/10.1038/s41598-023-38550-7
Dixit A, Ashish A, Sharma R. A comparative study on efficacy of fixed combination timolol/brinzolamide versus travoprost monotherapy in drug-naïve open-angle glaucoma patients. Ther Adv Ophthalmol. 2020;12.
Lanza M, Leone A, Scognamiglio G, Serra L, Iodice CM, Melillo P, et al. Evaluation of the Efficacy Duration of Topical Therapies in Eyes with Primary Open-Angle Glaucoma. J Clin Med. 2022;11(20).
Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13(October):1–9.
Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277–84.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
